Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.

Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, Leighl NB, Shepherd FA, Xu W, Liu G, Hurry M, O'Kane GM.

Cancer Med. 2019 Oct 24. doi: 10.1002/cam4.2603. [Epub ahead of print]

2.

Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.

Lee MJ, Kuehne N, Hueniken K, Liang S, Rai S, Sorotsky H, Herman M, Shepshelovich D, Bruce J, Liang M, Patel D, Cheng D, Chen Z, Eng L, Brown MC, Cho J, Leighl NB, de Perrot M, Reisman D, Xu W, Bradbury PA, Liu G.

Mol Carcinog. 2019 Nov;58(11):1960-1973. doi: 10.1002/mc.23088. Epub 2019 Jul 29.

PMID:
31355511
3.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, Leighl N, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L.

Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1.

PMID:
31200828
4.

A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS).

Veitch Z, Zer A, Loong H, Salah S, Masood M, Gupta A, Bradbury PA, Hogg D, Wong A, Kandel R, Charames GS, Abdul Razak AR.

Sci Rep. 2019 May 14;9(1):7390. doi: 10.1038/s41598-019-43222-6.

5.

The economic impact of the transition from branded to generic oncology drugs.

Cheung WY, Kornelsen EA, Mittmann N, Leighl NB, Cheung M, Chan KK, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE.

Curr Oncol. 2019 Apr;26(2):89-93. doi: 10.3747/co.26.4395. Epub 2019 Apr 1.

6.

The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.

O'Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB.

Lung Cancer. 2019 May;131:86-89. doi: 10.1016/j.lungcan.2019.03.019. Epub 2019 Mar 20.

PMID:
31027703
7.

The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.

O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G.

Oncologist. 2019 Jul;24(7):e501-e509. doi: 10.1634/theoncologist.2018-0544. Epub 2019 Apr 5.

PMID:
30952820
8.

Prostaglandin E2, but not cAMP nor β2-agonists, induce tristetraprolin (TTP) in human airway smooth muscle cells.

Bradbury P, Patel BS, Cidem A, Nader CP, Oliver BG, Ammit AJ.

Inflamm Res. 2019 May;68(5):369-377. doi: 10.1007/s00011-019-01224-0. Epub 2019 Mar 9.

PMID:
30852628
9.

The genetic architecture of teosinte catalyzed and constrained maize domestication.

Yang CJ, Samayoa LF, Bradbury PJ, Olukolu BA, Xue W, York AM, Tuholski MR, Wang W, Daskalska LL, Neumeyer MA, Sanchez-Gonzalez JJ, Romay MC, Glaubitz JC, Sun Q, Buckler ES, Holland JB, Doebley JF.

Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5643-5652. doi: 10.1073/pnas.1820997116. Epub 2019 Mar 6.

10.

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB.

Clin Lung Cancer. 2019 Jul;20(4):231-236. doi: 10.1016/j.cllc.2018.12.010. Epub 2018 Dec 22.

PMID:
30797721
11.

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Tomasini P, Mascaux C, Jao K, Labbe C, Kamel-Reid S, Stockley T, Hwang DM, Leighl NB, Liu G, Bradbury PA, Pintilie M, Tsao MS, Shepherd FA.

Clin Lung Cancer. 2019 May;20(3):e338-e345. doi: 10.1016/j.cllc.2018.12.009. Epub 2018 Dec 19.

PMID:
30770327
12.

Regional protein expression in human Alzheimer's brain correlates with disease severity.

Xu J, Patassini S, Rustogi N, Riba-Garcia I, Hale BD, Phillips AM, Waldvogel H, Haines R, Bradbury P, Stevens A, Faull RLM, Dowsey AW, Cooper GJS, Unwin RD.

Commun Biol. 2019 Feb 4;2:43. doi: 10.1038/s42003-018-0254-9. eCollection 2019.

13.

EP2 and EP4 receptor antagonists: Impact on cytokine production and β2 -adrenergic receptor desensitization in human airway smooth muscle.

Bradbury P, Rumzhum NN, Ammit AJ.

J Cell Physiol. 2019 Jul;234(7):11070-11077. doi: 10.1002/jcp.27938. Epub 2018 Dec 7.

PMID:
30536718
14.

Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.

Soldera SV, Kavanagh J, Pintilie M, Leighl NB, de Perrot M, Cho J, Hope A, Feld R, Bradbury PA.

Oncologist. 2019 Jul;24(7):e510-e517. doi: 10.1634/theoncologist.2018-0501. Epub 2018 Nov 26.

PMID:
30478189
15.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA.

Invest New Drugs. 2019 Jun;37(3):498-506. doi: 10.1007/s10637-018-0680-z. Epub 2018 Oct 13.

PMID:
30317534
16.

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Jao K, Tomasini P, Kamel-Reid S, Korpanty GJ, Mascaux C, Sakashita S, Labbé C, Leighl NB, Liu G, Feld R, Bradbury PA, Hwang DM, Pintilie M, Tsao MS, Shepherd FA.

Lung Cancer. 2018 Sep;123:22-29. doi: 10.1016/j.lungcan.2018.06.023. Epub 2018 Jun 19.

PMID:
30089591
17.

Repurposing of statins via inhalation to treat lung inflammatory conditions.

Bradbury P, Traini D, Ammit AJ, Young PM, Ong HX.

Adv Drug Deliv Rev. 2018 Aug;133:93-106. doi: 10.1016/j.addr.2018.06.005. Epub 2018 Jun 8. Review.

PMID:
29890243
18.

Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.

Zer A, Sung MR, Walia P, Khoja L, Maganti M, Labbe C, Shepherd FA, Bradbury PA, Feld R, Liu G, Iazzi M, Zawisza D, Nouriany N, Leighl NB.

Clin Lung Cancer. 2018 Sep;19(5):426-434.e1. doi: 10.1016/j.cllc.2018.04.008. Epub 2018 May 8.

PMID:
29803574
19.

Expanding the BLUP alphabet for genomic prediction adaptable to the genetic architectures of complex traits.

Wang J, Zhou Z, Zhang Z, Li H, Liu D, Zhang Q, Bradbury PJ, Buckler ES, Zhang Z.

Heredity (Edinb). 2018 Dec;121(6):648-662. doi: 10.1038/s41437-018-0075-0. Epub 2018 May 16.

20.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
21.

Increased experimental conditions and marker densities identified more genetic loci associated with southern and northern leaf blight resistance in maize.

Li YX, Chen L, Li C, Bradbury PJ, Shi YS, Song Y, Zhang D, Zhang Z, Buckler ES, Li Y, Wang T.

Sci Rep. 2018 May 1;8(1):6848. doi: 10.1038/s41598-018-25304-z.

22.

Dysregulation of expression correlates with rare-allele burden and fitness loss in maize.

Kremling KAG, Chen SY, Su MH, Lepak NK, Romay MC, Swarts KL, Lu F, Lorant A, Bradbury PJ, Buckler ES.

Nature. 2018 Mar 22;555(7697):520-523. doi: 10.1038/nature25966. Epub 2018 Mar 14.

PMID:
29539638
23.

18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.

Elliott HS, Metser U, de Perrot M, Cho J, Bradbury P, Veit-Haibach P, Hussey D, Noam T.

Br J Radiol. 2018 Jun;91(1086):20170814. doi: 10.1259/bjr.20170814. Epub 2018 Mar 29.

24.

Genomic features shaping the landscape of meiotic double-strand-break hotspots in maize.

He Y, Wang M, Dukowic-Schulze S, Zhou A, Tiang CL, Shilo S, Sidhu GK, Eichten S, Bradbury P, Springer NM, Buckler ES, Levy AA, Sun Q, Pillardy J, Kianian PMA, Kianian SF, Chen C, Pawlowski WP.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12231-12236. doi: 10.1073/pnas.1713225114. Epub 2017 Oct 30.

25.

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA.

Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19.

26.

Novel Loci Underlie Natural Variation in Vitamin E Levels in Maize Grain.

Diepenbrock CH, Kandianis CB, Lipka AE, Magallanes-Lundback M, Vaillancourt B, Góngora-Castillo E, Wallace JG, Cepela J, Mesberg A, Bradbury PJ, Ilut DC, Mateos-Hernandez M, Hamilton J, Owens BF, Tiede T, Buckler ES, Rocheford T, Buell CR, Gore MA, DellaPenna D.

Plant Cell. 2017 Oct;29(10):2374-2392. doi: 10.1105/tpc.17.00475. Epub 2017 Oct 2.

27.

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).

Labbé C, Cabanero M, Korpanty GJ, Tomasini P, Doherty MK, Mascaux C, Jao K, Pitcher B, Wang R, Pintilie M, Leighl NB, Feld R, Liu G, Bradbury PA, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.

PMID:
28838393
28.

Maize YABBY Genes drooping leaf1 and drooping leaf2 Regulate Plant Architecture.

Strable J, Wallace JG, Unger-Wallace E, Briggs S, Bradbury PJ, Buckler ES, Vollbrecht E.

Plant Cell. 2017 Jul;29(7):1622-1641. doi: 10.1105/tpc.16.00477. Epub 2017 Jul 11.

29.

Uncommon EGFR mutations in advanced non-small cell lung cancer.

O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA.

Lung Cancer. 2017 Jul;109:137-144. doi: 10.1016/j.lungcan.2017.04.016. Epub 2017 Apr 27. Review.

PMID:
28577943
30.

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.

Chia SK, Ellard SL, Mates M, Welch S, Mihalcioiu C, Miller WH Jr, Gelmon K, Lohrisch C, Kumar V, Taylor S, Hagerman L, Goodwin R, Wang T, Sakashita S, Tsao MS, Eisenhauer E, Bradbury P.

Breast Cancer Res. 2017 May 2;19(1):54. doi: 10.1186/s13058-017-0836-3.

31.

Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer.

Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbé C, Mascaux CM, Martin P, Kamel-Reid S, Tsao MS, Pintilie M, Liu G, Bradbury PA, Feld R, Leighl NB, Chung C, Shepherd FA.

Radiother Oncol. 2017 May;123(2):195-202. doi: 10.1016/j.radonc.2017.03.007. Epub 2017 Mar 28.

PMID:
28363487
32.

Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.

de Perrot M, Dong Z, Bradbury P, Patsios D, Keshavjee S, Leighl NB, Hope A, Feld R, Cho J.

Eur Respir J. 2017 Mar 15;49(3). pii: 1601428. doi: 10.1183/13993003.01428-2016. Print 2017 Mar.

33.

The focal adhesion targeting domain of p130Cas confers a mechanosensing function.

Bradbury PM, Turner K, Mitchell C, Griffin KR, Middlemiss S, Lau L, Dagg R, Taran E, Cooper-White J, Fabry B, O'Neill GM.

J Cell Sci. 2017 Apr 1;130(7):1263-1273. doi: 10.1242/jcs.192930. Epub 2017 Feb 21.

34.

HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy.

Notsuda H, Bradbury PA, Tsao MS.

J Thorac Oncol. 2017 Mar;12(3):422-424. doi: 10.1016/j.jtho.2017.01.007. No abstract available.

35.

Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review.

Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis PM.

Clin Lung Cancer. 2017 May;18(3):259-273.e8. doi: 10.1016/j.cllc.2016.07.002. Epub 2016 Jul 12. Review.

PMID:
28162945
36.

Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.

Labbé C, Leung Y, Silva Lemes JG, Stewart E, Brown C, Cosio AP, Doherty M, O'Kane GM, Patel D, Cheng N, Liang M, Gill G, Rett A, Naik H, Eng L, Mittmann N, Leighl NB, Bradbury PA, Shepherd FA, Xu W, Liu G, Howell D.

Clin Lung Cancer. 2017 Jul;18(4):388-395.e4. doi: 10.1016/j.cllc.2016.12.015. Epub 2016 Dec 28.

PMID:
28111120
37.

The Triticeae Toolbox: Combining Phenotype and Genotype Data to Advance Small-Grains Breeding.

Blake VC, Birkett C, Matthews DE, Hane DL, Bradbury P, Jannink JL.

Plant Genome. 2016 Jul;9(2). doi: 10.3835/plantgenome2014.12.0099.

38.

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Liu G, Cuffe S, Liang S, Azad AK, Cheng L, Brhane Y, Qiu X, Cescon DW, Bruce J, Chen Z, Cheng D, Patel D, Tse BC, Laurie SA, Goss G, Leighl NB, Hung R, Bradbury PA, Seymour L, Shepherd FA, Tsao MS, Chen BE, Xu W, Reisman DN.

Clin Cancer Res. 2017 May 15;23(10):2460-2470. doi: 10.1158/1078-0432.CCR-16-1640. Epub 2016 Nov 8.

39.

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207.

Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA.

J Thorac Oncol. 2016 Nov;11(11):2018-2021. doi: 10.1016/j.jtho.2016.06.024. Epub 2016 Jul 20.

40.

A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.

Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, Shepherd FA, Chung C, Ng R, Seymour L, Leighl NB.

Clin Lung Cancer. 2017 Jan;18(1):e41-e47. doi: 10.1016/j.cllc.2016.06.009. Epub 2016 Jul 9.

PMID:
27502323
41.

Genetic Architecture of Domestication-Related Traits in Maize.

Xue S, Bradbury PJ, Casstevens T, Holland JB.

Genetics. 2016 Sep;204(1):99-113. doi: 10.1534/genetics.116.191106. Epub 2016 Jul 13.

42.

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer.

Rayson D, Lupichuk S, Potvin K, Dent S, Shenkier T, Dhesy-Thind S, Ellard SL, Prady C, Salim M, Farmer P, Allo G, Tsao MS, Allan A, Ludkovski O, Bonomi M, Tu D, Hagerman L, Goodwin R, Eisenhauer E, Bradbury P.

Breast Cancer Res Treat. 2016 May;157(1):109-16. doi: 10.1007/s10549-016-3812-1. Epub 2016 Apr 26.

PMID:
27116183
43.

Identification of genetic variants associated with maize flowering time using an extremely large multi-genetic background population.

Li YX, Li C, Bradbury PJ, Liu X, Lu F, Romay CM, Glaubitz JC, Wu X, Peng B, Shi Y, Song Y, Zhang D, Buckler ES, Zhang Z, Li Y, Wang T.

Plant J. 2016 Jun;86(5):391-402. doi: 10.1111/tpj.13174. Epub 2016 Jun 20.

44.

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Cuffe S, Azad AK, Qiu X, Qiu X, Brhane Y, Kuang Q, Marsh S, Savas S, Chen Z, Cheng D, Leighl NB, Goss G, Laurie SA, Seymour L, Bradbury PA, Shepherd FA, Tsao MS, Chen BE, Xu W, Liu G.

Cancer Epidemiol. 2016 Apr;41:50-6. doi: 10.1016/j.canep.2015.12.012. Epub 2016 Jan 24.

PMID:
26816351
45.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Zer A, Ding K, Lee SM, Goss GD, Seymour L, Ellis PM, Hackshaw A, Bradbury PA, Han L, O'Callaghan CJ, Tsao MS, Shepherd FA.

J Thorac Oncol. 2016 Mar;11(3):312-23. doi: 10.1016/j.jtho.2015.11.010. Epub 2015 Dec 31.

46.

Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.

Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA.

Lung Cancer. 2015 Nov;90(2):288-95. doi: 10.1016/j.lungcan.2015.09.004. Epub 2015 Sep 16.

PMID:
26415995
47.

Construction of high-quality recombination maps with low-coverage genomic sequencing for joint linkage analysis in maize.

Li C, Li Y, Bradbury PJ, Wu X, Shi Y, Song Y, Zhang D, Rodgers-Melnick E, Buckler ES, Zhang Z, Li Y, Wang T.

BMC Biol. 2015 Sep 21;13:78. doi: 10.1186/s12915-015-0187-4.

48.

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.

Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ.

J Thorac Oncol. 2015 Jul;10(7):1099-106. doi: 10.1097/JTO.0000000000000548.

49.

Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.

Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L, Addison CL, Shepherd FA, Goss GD, Dimitroulakos J, Bradbury PA.

Clin Lung Cancer. 2015 Nov;16(6):e189-201. doi: 10.1016/j.cllc.2015.05.002. Epub 2015 May 13.

PMID:
26081815
50.

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Eigl BJ, North S, Winquist E, Finch D, Wood L, Sridhar SS, Powers J, Good J, Sharma M, Squire JA, Bazov J, Jamaspishvili T, Cox ME, Bradbury PA, Eisenhauer EA, Chi KN.

Invest New Drugs. 2015 Aug;33(4):969-76. doi: 10.1007/s10637-015-0252-4. Epub 2015 May 19.

PMID:
25983041

Supplemental Content

Loading ...
Support Center